PAPER Yadav A, Agrawal S, Tiwari SK, Chaturvedi RK
SEARCH RESULTS
329960 RESULTS
PAPER Fidaleo M, Fanelli F, Ceru MP, Moreno S
Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands.
Curr Med Chem. 2014 Mar 3; PubMed: 24606520PAPER Urbizu A, Canet-Pons J, Munoz-Marmol AM, Aldecoa I, Lopez MT, Compta Y, Alvarez R, Ispierto L, Tolosa E, Ariza A, Beyer K
Cystatin C is differentially involved in multiple system atrophy phenotypes.
Neuropathol Appl Neurobiol. 2014 Mar 10; PubMed: 24606172PAPER Olanow CW
Do prions cause Parkinson disease?: the evidence accumulates.
Ann Neurol. 2014 Mar;75(3):331-3. Epub 2014 Feb 24 PubMed: 24615832PAPER Wood H
Prion disease: Cerebrospinal fluid tau levels--a potential diagnostic biomarker for Creutzfeldt-Jakob disease.
Nat Rev Neurol. 2014 Apr;10(4):180. Epub 2014 Mar 11 PubMed: 24614517PAPER McCutcheon S, Langeveld JP, Tan BC, Gill AC, de Wolf C, Martin S, Gonzalez L, Alibhai J, Blanco AR, Campbell L, Hunter N, Houston EF
Prion protein-specific antibodies that detect multiple TSE agents with high sensitivity.
PLoS One. 2014;9(3):e91143. Epub 2014 Mar 7 PubMed: 24608105PAPER Torsney KM, Noyce AJ, Doherty KM, Bestwick JP, Dobson R, Lees AJ
Bone health in Parkinson's disease: a systematic review and meta-analysis.
J Neurol Neurosurg Psychiatry. 2014 Mar 21; PubMed: 24620034PAPER Bolitho SJ, Naismith SL, Terpening Z, Grunstein RR, Melehan K, Yee BJ, Coeytaux A, Gilat M, Lewis SJ
Investigating rapid eye movement sleep without atonia in Parkinson's disease using the rapid eye movement sleep behavior disorder screening questionnaire.
Mov Disord. 2014 Mar 11; PubMed: 24619826PAPER Liu RP, Zou M, Wang JY, Zhu JJ, Lai JM, Zhou LL, Chen SF, Zhang X, Zhu JH
Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling.
J Neuroinflammation. 2014 Mar 12;11:47. PubMed: 24618100PAPER
New research holds promise for Parkinson's treatment. New drugs and stem cell research offer encouraging glimpses of future therapies.
Duke Med Health News. 2013 Dec;19(12):1-2. PubMed: 24616930PAPER Morgan JC Jr, Currie LJ, Harrison MB, Bennett JP, Trugman JM, Wooten GF
Mortality in levodopa-treated Parkinson's disease.
Parkinsons Dis. 2014;2014:426976. Epub 2014 Jan 28 PubMed: 24616821PAPER Litvan I, Kong M
Rate of decline in progressive supranuclear palsy.
Mov Disord. 2014 Apr;29(4):463-8. Epub 2014 Feb 24 PubMed: 24615741PAPER Levin J, Schmidt F, Boehm C, Prix C, Bötzel K, Ryazanov S, Leonov A, Griesinger C, Giese A
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.
Acta Neuropathol. 2014 Mar 11; PubMed: 24615514PAPER Lotan I, Treves TA, Roditi Y, Djaldetti R
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.
Clin Neuropharmacol. 2014 Mar-Apr;37(2):41-4. PubMed: 24614667PAPER Sahin G, Thompson LH, Lavisse S, Ozgur M, Rbah-Vidal L, Dollé F, Hantraye P, Kirik D
Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
PLoS One. 2014;9(3):e90759. Epub 2014 Mar 10 PubMed: 24614598Current Filters
No filters selected